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Abstract 37 
Systemic sclerosis is an autoimmune connective tissue disease in which T cells play a prominent role. 38 
We and others have previously demonstrated a role for T cell-derived IL-13 in mediating the 39 
induction of collagen in dermal fibroblasts and that blockade with IL-13 antibodies attenuates this 40 
increase. In this study we want to probe the signalling that underpins IL-13 mediated matrix 41 
deposition. Isolated dermal fibroblasts were incubated with recombinant IL-13 and gene expression 42 
by qRT-PCR was performed for collagen1A1 and TGF-β1. Small interfering RNA (siRNA) was used to 43 
knock down STAT6 and a small molecule inhibitor was also used to block this pathway. MiR-135b 44 
was transfected into fibroblasts plus and minus IL-13 to see if this miR plays a role. miR-135b was 45 
measured in systemic sclerosis fibroblasts isolated from patients and also in serum. Results showed 46 
that IL-13 increased collagen expression and that this is independent from TGF-β1. This is dependent 47 
on STAT6 as targeting this blocked induction. MiR-135b reduces collagen induction in fibroblasts and 48 
scleroderma fibroblasts have lower constitutive levels of the miR. We further demonstrate that 49 
miR135b is repressed by methylation and may include MeCP2. In conclusion we show that STAT6 50 
and miR-135b regulate IL-13-mediated collagen production by fibroblasts.  51 
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Introduction 73 
Systemic sclerosis (SSc) is a polygenic, idiopathic connective tissue disease characterised by 74 
autoimmunity, vascular damage, inflammation and fibrosis. Activation of quiescent fibroblasts into 75 
myofibroblasts that express alpha-smooth muscle actin and secrete excessive extracellular matrix 76 
molecules is critical to the fibrosis that underpins the disease pathogenesis 1 and underpins fibrosis 77 
whatever organ is affected. 78 
Tissue fibrosis leads to excessive scarring that ultimately leads to loss of organ function and currently 79 
there is no disease modifying drug approved for treatment and there is substantial morbidity and 80 
mortality. Experimental studies show a clear link between the inflammation and fibrosis and many 81 
diverse cell types are involved in the inflammation and fibrosis. It has been shown that monocytes 82 
and T cells infiltrate the dermis in SSc especially prominent in early disease. T cells are particularly 83 
prominent early in the disease. Activation of T cells has been shown by the expression of T cell 84 
activation markers 2. SSc is characterised by elevated IL-4 and IL-13 levels in serum 3, 4 and 85 
abnormalities in Th2 cells. Indeed there is a correlation between IL-13 serum levels and nailfold 86 
capillaroscopy abnormalities in SSc patients 5. We demonstrated that T cell isolated from skin have 87 
upregulated expression of Tumour Necrosis Factor-α (TNF-α) receptors and Interleukin-13 (IL-13) 6 in 88 
SSc patients. Engagement of IL-13 (or IL-4) to its receptor IL-13R and the shared receptor IL-4Rα 89 
promotes Janus Kinase (JAK) activation that in turn leads to phosphorylation of STAT6, homodimer 90 
or heterodimer formation via their amino terminal domains, and translocation to the nucleus where 91 
they bind DNA, influencing gene expression in many cell types. STAT6 itself is important for the 92 
polarisation of naïve T cells to Th2 effector cells 7. This activation of STAT6 leads to activation of the 93 
transcription factor GATA3 which regulates the expression of Th2 cytokines such as IL-4 and IL-13 94 
thus differentiating the T cells to a Th2 phenotype 8 which appears to be the dominate T cell 95 
phenotype in SSc 3, 6. 96 
IL-13 and IL-4 have been shown to augment collagen gel contraction in in vitro models using 97 
pulmonary fibroblasts, suggesting matrix remodelling 9. Furthermore, overexpression of IL-13 in the 98 
lung in transgenic mice causes inflammation and lung fibrosis 10, and an IL-13 inhibitor blocks the 99 
development of fibrosis in a Th2 dominant animal model in which animals are exposed to 100 
shistosomiasis 11. Disruption of the IL-4 gene in the Tight skin mouse (Tsk), a model of SSc in which 101 
the gene for fibrllin is mutated, reduces the fibrosis 12. However, the mechanism by which IL-13 102 
cause’s fibrosis is still to be elucidated. 103 
MicroRNAs are small (around 21 nucleotides long) RNA molecules that function to regulate protein 104 
expression by translational inhibition or mRNA degradation through binding of the seed region with 105 
a complementary match site in the 3’UTR of the target mRNA 13. It is now known that there are 106 
many miRs in the genome and that each miR can target hundreds of genes, thus the level of 107 
regulation of expression is huge. Emerging evidence suggest that miRs are involved in virtually all 108 
cellular processes including growth, differentiation, apoptosis and fibrosis 14 and evidence has now 109 
been accrued that they are perturbed in multiple diseases. In SSc it has been found that there are 110 
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altered expression of various miRs and one of the most important is miR-29a which regulates 111 
collagen directly through binding to its 3’UTR 15 and enforced overexpression of miR-29a reduces 112 
collagen levels in SSc dermal fibroblasts. MiR-29a has also been identified in fibrosis of the heart 113 
after myocardial infarction 16. Strategies that restore the levels of miR29a in vitro and in vivo reduce 114 
fibrosis by targeting its mRNA target collagen1A1 15. Thus modulation of miRs in vivo is a possible 115 
therapeutic option in fibrosis. However, relatively few miRs have been described in SSc as compared 116 
to other diseases such as cancer or diabetes for example. MiRS themselves can be regulated 117 
epigenetically by methylation for instance and also histone modifications can also alter their 118 
expression. Thus all the epigenetic modifications can each affect one another and underpins the 119 
complexity of epigenetics. This study shows that miR-135b targets STAT6 and attenuates IL-13-120 
induced collagen expression. 121 
Results 122 
IL-13 induces collagen independent of TGF-β signalling 123 
Because we had previously demonstrated that IL-13 derived from T cells induces collagen expression 124 
in vitro we sought to confirm this in a ‘cleaner’ system free from other T cell cytokines 125 
‘contaminating’ the system. To confirm that IL-13 induces collagen in isolated dermal fibroblasts we 126 
performed a dose response study. Figure 1 demonstrates that 100 ng/ml of IL-13 induced the 127 
highest fold change of collagen1A1 mRNA expression peaking at 3.5 fold change in expression 128 
(normalised to 18S). This elevation of collagen was also found on the protein levels with a 72% 129 
increase in collagen compared to control after IL-13 treatment (100 ng/ml). There was no change in 130 
the expression of the myofibroblast marker α-smooth muscle actin expression by qRT-PCR at any 131 
concentration of IL-13. It has also been suggested that IL-13 induces TGF-β1 expression and release 132 
and that TGF-β1 is responsible for the collagen increase in a transgenic animal model of IL-13 133 
overexpression causing lung fibrosis 17. We did not observe any significant increase in TGF-β1 134 
expression after IL-13 stimulation by semi q-RT-PCR (figure 1B). Because TGF-β can also be activated 135 
from in its latent form to a biologically active motif by the matricellular protein Thrombospondin-1 136 
(TSP-1) 18, 19 we measured the levels of TSP-1 in the conditioned media. ELISA of TSP-1 levels in 137 
conditioned media after stimulation of dermal fibroblasts revealed no increase in secreted levels of 138 
TSP-1 between control or IL-13 stimulation (mean value: 440 vs 428 pg/ml, P =>0.05 Student’s t-139 
test). TGF-β1 stimulation served as a positive control and was significantly different compared to 140 
control and IL-13 treated (figure 1C). Direct measurement of TGF-β1 also showed no significant 141 
increase in expression (figure 1D). The target gene of TGF-β1 CTGF was also measured by RT-PCR 142 
and this was also not changed by the addition of exogenous recombinant IL-13 (data not shown). To 143 
confirm the role of TGF-β in IL-13 mediated collagen1A1 induction cells were pre treated with the 144 
TGF-βR inhibitor SB431542 and then stimulated with IL-13. Blockade of TGF-β signalling did not 145 
significantly attenuate IL-13-mediated induction of collagen (figure 1E), thus indicating that TGF-β 146 
signalling is independent of this effect. We further examined the expression of BMP and Activin 147 
Membrane-Bound Inhibitor (BAMBI) which is part of the TGF family and is a negative regulator of 148 
TGF-β1 signalling and found that this was not different after IL-13 (1 fold control versus 0.89 IL-13 149 
stimulated expression). 150 
IL-13 utilises STAT6 in collagen induction 151 
To examine the role of the transcription factor Signal Transducer and Activator of Transcription-6 152 
(STAT-6) in IL-13 mediated collagen expression we used siRNA to deplete dermal fibroblasts of 153 
STAT6. It was demonstrated that IL-13 addition (100 ng/ml) induced collagen1A1 expression, but this 154 
was reduced by pre-treatment with specific siRNA against STAT6 significantly to 1.6 fold change 155 
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compared to control. Importantly, this was not reduced by the introduction of equivalent 156 
concentration of scrambled control siRNA indicating its specificity (figure 2A) (P= <0.05 ANOVA). 157 
Furthermore, chemical inhibition of STAT6 with the STAT6 specific inhibitor AS1517499 20 (40 nM) 158 
lead also to a reduction of IL-13 mediated increases in collagen expression as compared to control 159 
untreated cells (figure 2B).  Figure 2C demonstrates the efficiency of the siRNAs against STAT6 by 160 
measuring STAT6 transcripts with a 60% reduction in STAT6 transcripts after transfection of the 161 
STAT6 siRNA and also protein expression (Student’s t test) (figure 2D protein reduction). 162 
miR-135b regulates IL-13-mediated collagen expression 163 
We then used computational algorithm prediction software to identify possible miRs that target the 164 
downstream signal molecule STAT6. These computer prediction software work on the basis of 165 
putative seed pairing between the ‘seed’ region in the miR and the 3’UTR in its target mRNA thus 166 
leading to target mRNA repression. These identified miR-135b as a miR likely to target STAT6 directly 167 
through this seed region. Transfection of synthetic miR-135b mimics into dermal fibroblasts 168 
attenuated the IL-13 induction of collagen1A1 expression; however the scrambled miR did not 169 
attenuate the collagen induction by IL-13 stimulation (100 ng/ml) figure 3A (Significantly different 170 
between control vs IL-13 treated and IL-13 treated plus miR135b mimic. No significant difference 171 
between IL-13 treated vs IL-13 treated and scrambled miR mimic, ANOVA). To confirm that 172 
transfection of miR-135b into the fibroblast was efficient in these cells we transfected a high and low 173 
concentration and then measured the miR levels 24 hours later using qRT-PCR. Figure 3B 174 
demonstrates the expression of miR-135b after transfection of low and high dose miR-135b. Figure 175 
3C also demonstrates that transfection of miR-135b alone reduces STAT6 mRNA levels significantly. 176 
However, it did not alter the levels of a similar STAT, STAT3 (figure 3D). Interestingly, miR-135b has a 177 
binding site for the 3’UTR of Monocyte Chemoattraction Protein 3/CCL7 and should target this 178 
directly we therefore measured MPC-3 after transfection of miR-135b. There was a reduction after 179 
transfection of miR-135b of MCP-3 gene expression. 180 
Reduced levels of miR-135b in SSc fibroblasts and elevated STAT6 181 
The target of miR135b is STAT6 due to the prediction software analysis and also because of the 182 
reduction of STAT6 with synthetic miRs we measured the levels in dermal fibroblasts in SSc patients 183 
and found this to be elevated (figure 4A). Because we had found that miR-135b was regulating 184 
STAT6 and mediating collagen expression we examined the levels of miR-135b in SSc dermal 185 
fibroblasts. We found a reduced expression of miR-135b levels in SSc compared to control 186 
fibroblasts, however, this did not quite reach statistical significance (figure 4B). Because TGF-β1 is a 187 
critical cytokine in fibrosis and is highly elevated in SSc we treated cells with TGF-β1 (10 ng/ml) to 188 
see if this reduced miR-135b. Unexpectedly, TGF-β1 stimulation led to a 2 fold increase miR-135b 189 
expression compared to untreated healthy control fibroblasts (P =0.0354 Student’s t-test) (figure 190 
4C), this was opposite to what we had hypothesised. 191 
Dermal fibroblasts isolated from SSc patients were examined for IL-4Rα expression as this is the 192 
receptor subunit used by IL-13 (and IL-4) upstream of STAT6 and is common receptor through which 193 
both cytokines signal. There was no clear difference in expression of the IL-4 receptor in SSc 194 
fibroblasts (figure 4D). Because reactive oxidative species has been shown to play a prominent role 195 
in fibrosis in SSc we incubated healthy control dermal fibroblast cells with sub toxic concentrations 196 
H202 to examine its effect on IL-4Rα expression. MTT assay demonstrated that the H202 treated 197 
cells were not dying. qPCR demonstrated no significant difference in IL-4R expression between H202 198 
treated and non-treated cells (P=> 0.05; Student’s t test). 199 
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Levels of serum and monocyte miR-135b 200 
It has recently been discovered that miRs can also be extracellular and that these miRs are enclosed 201 
within vesicles called exosomes rendering them remarkably stable. Patient and healthy control 202 
serum was isolated and measured for miR-135b by qRT-PCR and this demonstrated highly 203 
significantly reduced levels of miR-135b compared to healthy controls (P =0.0060 Student’s t test) 204 
(figure 5A). To elucidate this further we measured the levels of miR-135b in isolated CD14+ 205 
monocytes in patients and found this was significantly lower compared to controls (figure 5B). 206 
Bleomycin treated mice have lower miR-135b levels 207 
A useful model of skin fibrosis is the bleomycin model in which instillation of the compound 208 
bleomycin into the mouse results in inflammation-driven fibrosis that recapitulates the fibrosis in 209 
SSc. We measured the levels of miR-135b in the skin of mice treated with bleomycin or vehicle 210 
control treated mice and found highly significantly reduced levels of miR-135b (P =0.0001; Student’s 211 
t test) figure 5C). Pro- fibrotic TIMP-1 mRNA was also significantly elevated in the bleomycin mouse 212 
tissue compared to vehicle control (figure 5D).  213 
Regulation of miR135b levels 214 
Because the miR appears to be regulating its target STAT6 and we had demonstrated STAT6 is 215 
altering collagen levels and in SSc cells the miR was downregulated we wondered what is regulating 216 
the repression of the miR itself? Examining the promoter sequence of the miR135b gene it could be 217 
seen that it has CpG sites that could be methylated we therefore incubated healthy dermal 218 
fibroblasts with the global demethylating agent 5’azaC which sequesters DNMT enzyme activity. 219 
Incubation with 5’aza lead to significant upregulation of miR135b levels of 9 fold compared to 220 
vehicle treated cells (figure 6A) (P= <0.001 Student’s t test). However the same incubation of 5’azaC 221 
did not lead to upregulation of the unrelated microRNA miR133a compared to vehicle control 222 
treated cells (figure 6B). This indicates methylation is important in its regulation. In general 223 
hypermethylation leads to gene repression and hypomethylation leads to enhanced gene 224 
expression. Cytosine is the base that is methylated generating 5’methyl cytosine and it is now known 225 
that TET enzymes are the enzymes responsible for removing this modification and appear important 226 
in demethylation. We hypothesised that a reduction in the SSc dermal fibroblasts would be present 227 
leading to altered demethylation. Figure 6C demonstrated no difference in TET1 levels suggesting 228 
this is not a factor influencing this. We further examined the expression of the methyltransferase 229 
enzyme Enhancer of Zeste Homolouge 2 (Ezh2) which is important for the transfer of methyl groups 230 
and this was reduced in the SSc fibroblasts but not statistically significant (figure 6D). There was also 231 
no significant difference in the methyltransferase ASH1 (figure 6D). ASH1 is part of the trithorax 232 
proteins and was recently shown to regulate fibrosis by binding directly to the TIMP-1 promoter.  233 
Methyl cap binding protein 2 (MeCP2) is the protein most associated with the disease Rett syndrome 234 
but is ubiquitously expressed 21. This acts by binding to DNA to repress the DNA gene expression by 235 
binding in its methyl binding domain. Because of its repressive function in DNA we examined its 236 
expression. We found that MeCP2 is significantly enhanced in SSc dermal fibroblasts compared to 237 
control fiboblastss (figure 6E). Furthermore in normal dermal fibroblasts exposure to TGF-β1 leads to 238 
significant elevation of MeCP2 expression, but does not appear to be dose dependant (figure 6F). 239 
Demethylation reduces collagen levels 240 
We have shown that miR135b is regulated by methylation and that this could be mediated by the 241 
repressive protein MeCP2 so we examined the effects of 5’aza’c on collagen expression in 242 
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fibroblasts. Exposure to 5’aza’C reduced the levels of collagen1A1 compared to vehicle control 243 
treated cells in healthy dermal fibroblasts (figure 7A). (P= <0.001 Student’s t test). 244 
Using SSc dermal fibroblasts we also found a significant reduction in collagen levels after 5’azaC 245 
treatment also (figure 7B) (Student’s t test P= <0.05). However, we could see no significant 246 
difference in CTGF levels (figure 7C). 247 
 248 
 249 
 250 
Discussion 251 
Extracellular Matrix (ECM) production involves responses to endogenous and exogenous factors that 252 
promote production of ECM or inhibit the breakdown of ECM. Excessive production leads to scarring 253 
and fibrosis and is especially prominent in SSc. IL-13 is a pro fibrotic molecule that is produced by T 254 
cells that activates ECM production and is a feature of many fibrotic diseases but its molecular 255 
mechanism is not well described. IL-13 is elevated in SSc and is associated with disease specific 256 
features such as nailfold capillary defects 5 and IL-13 producing T cells are found within the skin. 257 
Here we demonstrate that it is STAT6-dependant and that miR-135b regulates STAT6 by targeting 258 
mRNA and that this miR may be reduced through a methylation dependant mechanism that may 259 
include MeCP2. 260 
IL-13 has been demonstrated to be elevated in the bleomycin model of fibrosis and activation of the 261 
pregnane X receptor blocked the bleomycin induced fibrosis and this was not mediated directly but 262 
through reducing the expulsion of IL-13 from murine T cells to activate the fibroblasts to secrete 263 
ECM 22, demonstrating the critical role of T cell mediated IL-13 in fibrosis. IL-13 has also been 264 
described to supress MMP-13 in isolated dermal fibroblasts thus decreasing the proteolytic 265 
degradation of ECM favouring an increase in deposition 23 and also reduce MMP-3 release by ocular 266 
conjunctiva fibroblasts and in lung fibroblasts IL-13 has been shown to induce Platelet Derived 267 
Growth Factor (PDGF) release 24. 268 
We have previously demonstrated that T cell-derived IL-13 can induce collagen transcription in 269 
healthy dermal fibroblasts in culture 6 and it is generally accepted that SSc has a Th2 dominance with 270 
increased Th2 cytokines both locally and in the sera 4 and these foster the release of ECM. 271 
Furthermore, Fuschiotti et al using multi colour flow cytometry demonstrated that it is effector CD8+ 272 
T cells that are the highest producers of IL-13 in SSc, even though CD4+ T cells also display 273 
production 25. They also found this CD8+ T cell production of IL-13 is associated with diffuse 274 
cutaneous SSc more so than limited SSc 25. This has also been verified in a recent study with isolated 275 
CD8+ T cells 26. It has also been shown that CD8+ T cells isolated from patients with SSc mediates 276 
increased collagen1A and fibronectin expression in dermal fibroblasts in culture and that this can be 277 
blocked by incubation with an anti-IL-13 antibody, but not by an anti-IL-4 antibody or isotype control 278 
indicating this is IL-13 specific and not mediated through IL-4.  The authors also show that incubation 279 
of T cell supernatants with dermal fibroblasts promotes the phosphorylation of the transcription 280 
factor STAT6 assessed by flow cytometry. We had also seen a similar effect 6 in vitro. Indeed siRNA 281 
mediated silencing of GATA3 in SSc CD8+ T cells from patients diminished high basal unstimulated 282 
levels of IL-13. It has been published that IL-13-mediated increases in lung fibrosis by a transgene 283 
expressing mouse was facilitated by TGF-β1 and can be reduced by blocking the activation of TGF-β 284 
17, however we did not find any increase in TGF-β levels after IL-13 stimulation nor the TGF-β 285 
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activation protein TSP-1 19. Furthermore blockade of the TGF-βR with chemical inhibition had no 286 
effect on collagen induction by IL-13. We also found no change in BAMBI levels which is a negative 287 
regulator of TGF-β signalling by acting as a pseudo receptor. This is in line with data in which IL-13 288 
KO mice are protected from lung fibrosis but not IL-4 KO mice, despite the fact that they have 289 
abundant TGF-β1 levels. We demonstrate here that siRNA against STAT6 to silence the transcription 290 
factor diminishes the collagen induction mediated by IL-13 stimulation and this was also the case 291 
using the chemical STAT6 inhibitor that has previously been reported to inhibit STAT6 effects 20. 292 
Thus, STAT6 is critical in mediating this response. However, it appears that TGF-β does not play a 293 
role in this induction. IL-13 had been previously shown in lung fibroblasts to induce collagen through 294 
TGF-β in fibroblasts from asthma patients 27. It has recently been demonstrated that methylation of 295 
STAT6 determines its phosphorylation and modulates its DNA binding activity in response to 296 
exogenous stimulation 28, thus adding another layer of complex regulation Because IL-13 shares its 297 
signalling with the shared co receptor IL-4α we measured the levels of this, we could find no increase 298 
in IL-4α in SSc fibroblasts compared to controls and this could not be modulated by oxidative stress 299 
either, as ROS is important in fibrogenesis. 300 
Through computer prediction software we identified miR-135b as regulating STAT6 by binding to its 301 
3’UTR region. We confirmed this with transfection of miR-135b and the reduction of STAT6 and 302 
augmentation of IL-13 induction of collagen expression in these cells. Therefore, reduction of miR-303 
135b in SSc cells would lead to enhanced STAT6-mediated ECM induction. Interestingly we also 304 
observed reduction of MCP-3 which is predicted to be targeted by miR-135b as it has a binding site. 305 
This confirms transfection of the miR. MCP-3 is a chemoattractant for monocytes and monocytes are 306 
important in the disease and are often found in the skin of SSc patients. A study has shown that 307 
MCP-3 is elevated in SSc and the Tsk mouse model of fibrosis which has similar features to SSc. What 308 
actually modulates the levels of miR-135b is unknown and maybe a variety of soluble factors, 309 
possibly released by innate immune cells. We hypothesised that the pro fibrotic TGF-β1 would 310 
diminish miR-135b, however, it actually increased its expression. This may be part of a negative 311 
feedback loop to dampen down fibrosis, however further investigations are required. 312 
Using the bleomycin model which recapitulates features of the disease, we found also that miR135b 313 
was significantly reduced in bleomycin treated mice. Many miRs have now been identified in 314 
mediating a role in fibrosis, however only a very few have been described in SSc. We also show 315 
reduced levels of miR135b in SSc dermal fibroblasts. It is known that miR-29a is involved in SSc 15 and 316 
we have also demonstrated reduced levels of miR-29a in SSc dermal fibroblasts 29 and this targets 317 
collagen. Others have demonstrated down regulated miR let7-a in SSc by in situ hybridisation and 318 
qRT-PCR and found that this contributes to excessive collagen production 30. Similarly in keloid 319 
fibroblasts, which are abnormally excessive ECM type fibroblasts aberrant expression of miRs has 320 
been demonstrated to mediate collagen1 expression 31. The finding that miR-135b regulates collagen 321 
expression via direct targeting of STAT6 further supports the notion that dysregulated miRs play a 322 
role in fibrosis.  323 
MiRs are very stable in serum and are released enclosed within membrane bound vesicles called 324 
exosomes. These exosomes appear to protect the miR from endogenous RNAses that would 325 
otherwise degrade the miR.  We demonstrate for the first time reduced serum miR135b levels in SSc 326 
patients compared to healthy controls. The significance of this is unknown but in further larger 327 
studies if this is replicated this may be a potential biomarker. Because there were differences in 328 
serum levels we sought to identify another cell type that might responsible for this, We found 329 
significantly reduced levels in CD14+ monocytes in SSc patients. The significance of this is not clear 330 
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but one would expect its target STAT6 also to be elevated in the monocytes. STAT6 in monocytes is 331 
important in M2 differentiation and these are important in wound healing.  332 
We sought to identify what is underlying the repression of miR135b and because it was noted that it 333 
has CpG sites that can be methylated in its promoter we hypothesised that the miR is 334 
hypermethylated. We show through the use of the hypomethylating agent 5’aza’C that the miR was 335 
elevated after treatment compared to vehicle control and furthermore an unrelated miR, miR133a 336 
was not changed, suggesting that this is a specific event rather than a global one. Because it is now 337 
known that TET1 enzyme is critical in the demethylation we examined the expression of this enzyme 338 
in healthy and SSc fibroblasts and found no significant difference between the groups.  339 
MeCP2 is a methylated binding protein that binds to methylated DNA to facilitate a repressive state 340 
21 and we hypothesised this may be modulated in SSc. We examined the levels of MeCP2 and found 341 
this to be elevated in SSc fibroblasts. MeCP2 is part of a family of methyl CpG binding proteins and is 342 
the most abundantly expressed member of this family 21. Mutations in the protein are more 343 
commonly associated with Rett syndrome a rare X-linked neurodevelopmental disorder affecting 1 344 
in 10000 females 32. Mutations are often found in the methyl binding domain of the protein and lead 345 
to alterations in its levels in the brain, however, it precise molecular effects are unknown. We 346 
demonstrate that elevated levels of MeCP2 may be associated with repression of miR135b and that 347 
this could be forming a complex with HDAC1. We also found large upregulation of MeCP2 in healthy 348 
cells upon TGF-β1 stimulation.  It is of note that a SNP in MeCP2 is associated with SSc 33. 349 
Furthermore, MeCP2 heterozygous mice have attenuated fibrosis in the liver after carbon 350 
tetrachloride instillation with much lower myofibroblasts and collagen content 34. Furthermore 351 
MeCP2 has been found in fibrotic hearts 35. This indicates that MeCP2 is critical in fibrosis. 352 
Interestingly their also appears to be some interaction in liver fibrosis between MeCP2 and the 353 
methyltransferase ASH1, where the increased expression of MeCP2 either through regulation of 354 
miRs or another mechanism appears to elevate ASH1 levels and increases ECM through direct 355 
binding of the genes in their promoters. Although we saw some elevation in SSc dermal fibroblasts 356 
of ASH1 this was not statistically significant. It is suggested that the repression of miR135b is due to 357 
methylation as there is methylation sites in the CpG islands in the miR135b promoter and due to the 358 
fact that hypomethylation led to an increase in miR levels. Although 5’Aza’c is none specific in 359 
demethylating it is suggested that it is demethylating the miR135b promoter and thus derepressing 360 
this. This repression may be aided by MeCP2 that is binding the methylated DNA and helping to 361 
repress it possibly in combination with HDAC1. In liver fibrosis this repression by MeCP2 and HDAC1 362 
leads to repression of PPAR-γ and consequent silencing of this gene, PPARγ itself is a negative 363 
regulator of fibrosis and the reduction of this releases the ECM genes to be expressed 34. Also a 364 
transgenic mouse over expressing MeCP2 has exacerbated heart fibrosis and enhanced scaring in 365 
response to pressure overload 36. 366 
Finally as well as the DNA demethylation increasing the levels of the miR it also demonstrated a 367 
reduction in collagen expression.  368 
In SSc dermal fibroblasts it has been shown that 5’Aza’C reduced hypermethylation of the Wnt 369 
antagonist DKK1 and Secreted Frizzled RP1 (SFRP1) and thus enhanced their expression and this was 370 
associated with a blockade of pro-fibrotic Wnt signalling and in vivo 5’Aza’C ameliorated bleomycin 371 
induced fibrosis 37. The blockade of fibrosis in the bleomycin model by hypomethylation could also 372 
have been due in part to reactivation of repressed miR135b. The fact that SSc fibroblasts in culture 373 
retain a fibrotic phenotype even over many passages suggests they have some sort of intrinsic 374 
‘memory’, this could be due to the methylation that is imprinted and retained over multiple cell 375 
divisions.  It has been demonstrated in cardiac fibroblasts that hypoxia induced fibrosis is driven by a 376 
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global hypermethylation 38. This increased methylation is genome-wide and mediated by a hypoxia 377 
inducible factor-dependant increase in DNMT3 as deletion in vitro of DNMT3 by siRNA reduced 378 
methylation and also collagen and α-Sma content 38. This indicates the global alteration of 379 
methylation is important in the differentiation of fibroblasts to myofibroblasts. The initial event that 380 
is driving the methylation in their study is hypoxia and the heart is particularly vulnerable to a 381 
hypoxic state. In our study we do not know what is increasing methylation but it is interesting to 382 
note that hypoxia is prevalent in SSc and hypoxia has been shown to increase collagen expression in 383 
dermal fibroblasts 39. It is suggested that hypoxia maybe leading to hypermethylation and increased 384 
ECM by repression of miR135b. It is also interesting to note that mice exposed to hypoxia 385 
experimentally have elevated ECM in their dermis 39. 386 
Immune perturbations are common in SSc and precede the fibrosis. Here we demonstrate that the T 387 
cell cytokine IL-13 mediates its effects through STAT6 and that STAT6-miR-135b are important in 388 
collagen increases. Reintroduction of miR-135b may be useful in STAT6-driven fibrosis. We also 389 
demonstrate the novel observation of elevated MeCP2 and that this may be important in SSc. 390 
Methods 391 
This study was approved by the local research ethics committee (REC no. 13/NE/0089 392 
and 091/H0905/11) and all patients gave fully informed written consent. All methods were carried 393 
out in accordance with the approved guidelines. Normal dermal fibroblasts were isolated from 394 
healthy volunteers by skin punch biopsy (6 mm3) and from clinically diagnosed limited SSc patients 395 
from the affected skin area and the tissue was placed into a six well plate with Dulbeccos modified 396 
Eagles Medium (DMEM) medium (Sigma) supplemented with 10% (vol/vol) heat-inactivated Fetal 397 
Calf Serum (FCS) (Gibco, UK) and 2 mM L-glutamine and 100U/ml penicillin/streptomycin at 37ºC in 398 
an atmosphere containing 5% CO2. After a few days cells were confluent and passaged using 399 
trypsin/EDTA (Gibco, UK) from the explant and all experiments were performed in early passaged 400 
cells (p2-8). Control tissue was derived from healthy donors undergoing corrective abdominal 401 
reduction (plastic) surgery N= 5. SSc patients were all female and not taking any immunosuppressive 402 
therapy or chemotherapy and all had clinically diagnosed limited SSc n=5 mean age 57 years old (all 403 
female SSc) taking no medication. The STAT6 inhibitor AS1517499 20 was purchased from 404 
AxonMedchem (USA) and was used at a final concentration of 40 nM in cell culture experiments. The 405 
TGF-β inhibitor SB431542 (Tocris Biosciences, UK) was used at a final concentration of 10 µM to 406 
inhibit the TGF-β signalling system. Fibroblasts were pre-treated for 2 hours with or without 407 
SB431542 after which time IL-13 was incubated 100 ng/ml with the TGF-β inhibitor still within the 408 
media, 24 hours later the cells were harvested. 409 
RT-PCR 410 
After cell stimulation cells were harvested in Trizol buffer and cellular RNA isolated according to the 411 
manufacturer’s instructions. RNA quality was assessed by nanodrop ND100 spectrophotometer with 412 
260/280nm readings. 1µg RNA was reverse transcribed to cDNA with superscript III (Invitrogen, UK) 413 
with RNAse inhibitor. Prepared cDNA was subjected to quantitative PCR using SYBR green Taq ready 414 
(Sigma, UK) technology using specific primers to the genes of interest using the specific primers 415 
(forward and reverse) below in a total volume of 25µl using the 7500 RT-PCR machine (Applied 416 
Biosciences, UK). Data was normalised to endogenous housekeeping gene 18S, which was confirmed 417 
to be stable across the groups and relative changes were calculated using the deltadelta Ct method 418 
with the control as the comparator. Collagen1A1: forward 5′-CAAGAGGAAGGCCAAGTCGAGG-3’, 419 
reverse 5’-CGTTGTCGCAGACGCAGAT-3′ 18S Forward: 5′ CGAATGGCTCATTAAATCAGTTATGG-3′ 420 
Reverse 5′-TATTAGCTCTAGAATTAC CACAGTTATCC-3′. STAT6: Forward: 5’-CCTCGTCACCAGTTGCTT-3’ 421 
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Reverse: 5’-TCCAGTGCTTTCTGCTCC-3’. STAT3: Forward: 5'-GGAGGAGTTGCAGCAAAAAG-3’ Reverse: 422 
5'-TGTGTTTGTGCCCAGAATGT-3' 423 
Absent, Small or Homeotic disc-1 (ASH1): Forward: 5’AATGATCTTTGCTGAGTGTT-3’ Reverse: 424 
TCCCCAACCTTTTTCCTCAG-3’. Connective Tissue Growth Factor Forward: 5′-CTCGCGGCTTACCGACTG-425 
3′ Reverse: 5′-GCACTTGAACTCCACCGG-3′ BMP And Activin Membrane-Bound Inhibitor (BAMBI): 426 
Forward: 5′-CGCCACTCCAGCTACATCTT-3′ Reverse: 5′-CAGATGTCTGTCGTGCTTGC-3’. 427 
Alpha Smooth muscle actin: Forward: 5’-TGAAGAGCATCCCACCCT-3’ Reverse: 50-428 
ACGAAGGAATAGCCACGC-3’. MCP-3/CCL7 Forward: 5’-TGTCCTTTCTCAGAGTGGTTCT-3’ Reverse: 5’-429 
TGCTTCCATAGGGACATCATA-3’ IL-4R Forward: 5’-CTGGAGCACAACATGAAAAGG-3’ Reverse: 5’-430 
AGTCAGGTTGTCTGGACTCTG-3’. MeCP2: Forward: 5’- GATCAATCCCCAGGGAAAAGC-3’ Reverse:  5’-431 
CCTCTCCCAGTTACCGTGAAG-3’. 432 
Semi quantitative PCR for TGF-β1 was performed using primers for TGF-β1 Forward: 5′-433 
GGATACCAACTATTGCTTCAGCTCC-3′ Reverse: 5′-AGGCTCCAAATATAGGGGCAGGGTC-3′ and the 434 
product ran on a 2% agarose gel containing ethidium bromide and visualised under UV light. 435 
ELISA for Thrombospondin-1 (TSP-1) and TGF-β1 436 
Healthy dermal fibroblasts were seeded into 24-well plates and at 80% confluence serum starved for 437 
24 hours after which recombinant IL-13 100 ng/ml or 10 ng/ml Transforming Growth Factor-β (a 438 
positive control) was added to serum free media and incubated for a further 24 hours. Conditioned 439 
medium was then collected and measured for TSP-1 using a human TSP-1 ELISA (R&D systems, UK) in 440 
accordance with the manufacturer’s instructions against a standard curve of recombinant TSP-1 441 
using a fluorescent plate reader (Tecan). The same supernatants were used to measure TGF-β1 442 
levels by ELISA (R&D systems, UK). 443 
siRNA knockdown 444 
For the siRNA silencing experiments cells were seeded into 24-well plates, and at 50–60% confluence 445 
100 nM STAT6 siRNA SMARTpool (Dharmacon, UK) 100 nM of none targeting control siRNA was 446 
transfected using DharmaFECT 1 in antibiotic and serum-free DMEM media. Following 24 h of 447 
incubation, medium was replaced with fresh medium FCS free medium supplemented with 448 
recombinant endotoxin-free IL-13 100 ng/ml (R&D systems, Abingdon, UK) and after a further 24 h 449 
cells were harvested for expression. 450 
Western Blotting 451 
After transfection with specific siRNA or none targeting control siRNA (100 nM) cells were lysed in 452 
RIPA buffer containing protease inhibitors. 25 µg of total protein was loaded in Lammeli buffer with 453 
beta-mecaptoethanol and ran on a 10% Polyacrylamide denaturing gel. The gel was transferred to 454 
onto nitrocellulose membrane with wet transfer, blocked for 1 hour in 5% blocking solution (non-fat 455 
milk) in TBS-tween and then hybridised overnight with anti-STAT6 antibody (Cell signal, 9362) 456 
overnight 1:800 at 4°C, washed three times in TBS-tween and then incubated with anti-Rabbit Horse 457 
Radish Peroxidase (HRP) antibody 1:4000 (Dako, UK) for 1 hour at room temperature, washed and 458 
then incubated with ECL substrate (Biorad, UK) and then exposed and developed. Healthy or SSc 459 
dermal fibroblast early passage were seeded and then lysed and then probed with anti-STAT6 1:800 460 
or Ten Eleven Translocation-1 (TET1) (Abcam, UK) 1:700 or GAPDH (Abcam, UK) 1:8000. In some 461 
experiments healthy dermal fibroblasts where treated with increasing doses of recombinant TGF-β1 462 
and then lysed and then probed for MeCP2 using an MeCP2 specific antibody (Ab2828) and the 463 
reprobed for β-actin (Ab8226). 464 
miR Experiments 465 
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miR-135b was identified by prediction software to bind the 3’UTR of STAT6 (Pictar software and 466 
Targetscan). Pre miR-135b (Thermo scientific, UK) was transfected into dermal fibroblasts at 75nM 467 
concentration using dharmaFECT1 transfection reagent in antibiotic and FCS-free medium along with 468 
control miR (75nM). The sequence of the control miR is designed to be complementary to the 469 
nematode worm C. elegans. To confirm successful transfection the miR was measured in the cells 470 
after transfection after three washes with sterile PBS (Sigma, UK) using qRT-PCR with specific 471 
primers for miR-135b (Applied Biosciences).  472 
H202 treatment 473 
Healthy dermal fibroblasts were grown to confluence and then treated with H202 (Sigma, UK) at sub 474 
toxic concentrations 200µM for 2 hours in FCS-free medium after 2 hours the H202 FCS-free medium 475 
was removed and replaced with complete medium containing 10% FCS and L-glutamine. These cells 476 
were left for 3 days after which RNA was isolated and cDNA generated and qPCR was performed for 477 
IL-4Rα with the primers described in the section above. 478 
Measurement of miR-135b 479 
MiR-135b was measured in SSc dermal fibroblasts and healthy control cells using qRT-PCR and 480 
normalised to let-7a levels using Taqman qPCR with primer specific reverse transcription. miR133a 481 
was also measured after 5aza’c treatment also. Serum levels of miR-135 was measured by qRT-PCR 482 
and also let7a after isolation with the miRNeasy RNA isolation kit (Qiagen, UK) following the 483 
manufacturer’s instructions. This serum miR study included larger number of patients as opposed to 484 
the dermal fibroblasts study. The number of patients was 15, n=10 diffuse SSc and limited SSc 485 
patients n=5.  In some experiments healthy control dermal fibroblasts were treated with TGF-β1 (10 486 
ng/ml) and after 24hrs RNA was harvested and qRT-PCR was performed for miR-135b and let7a as 487 
the endogenous internal control. In further experiments CD14+ monocytes where isolated from 488 
whole blood by negative selection and then RNA was isolated and miR-135b was measured along 489 
with let-7a. 490 
Collagen measurement 491 
Total soluble collagen in cell culture supernatants was quantified using the SirCol collagen assay 492 
(Biocolor, Belfast, UK) as per the manufacturer’s instructions. Which is an assay based on 493 
hydroxyproline. The dermal fibroblast where treated with nothing or IL-13 (100 ng/ml) and after 24 494 
hours the collagen protein was quantitated. Data was normalized to control which was set at 100% 495 
collagen. 496 
5’aza’2-deoxycytidine( 5’aza’C) treatment 497 
Human dermal fibroblasts were treated with 10 µM of 5’aza’C (Sigma, UK) or vehicle control DMSO 498 
for up to 5 days after which the miRs were measured as above. In separate experiments healthy and 499 
SSc fibroblasts were treated with 10µM 5’aza’C or vehicle for 5 days and qPCR was performed for 500 
collagen, CTGF and 18S. 501 
Bleomycin induced fibrosis 502 
Wild type C57BL/6 mice were used in this study.  All the mice where male and aged 8-10 weeks old 503 
at commencement of the study. Mice were anesthetised with isoflurane, their backs shaved and 100 504 
µl 0.5 mg/ml bleomycin (Apollo Scientific, UK) or saline (vehicle control) administered via 505 
subcutaneous injection to an area approximately 1 cm2. Injections were repeated every other day 506 
for 4 weeks at which point mice were sacrificed (5 mice per group; treatment or vehicle).  507 
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Wax embedded sample processing for miR quantification 508 
Skin biopsies were taken from the vehicle treated and bleomycin treated mice placed in 10% 509 
formaldehyde for 16 hours after which time they were dehydrated through graded ethanols and 510 
then placed in zylene, samples were then embedded into wax and then sectioned. 10μm sections 511 
were then used to isolate RNA using the miRNeasy FFPE kit (Qiagen, UK) which includes removing 512 
from the paraffin wax and treating with proteinase K digestion and isolation according to the 513 
manufacturer’s protocol. Tissue isolated RNA was measured for quality and reverse transcribed for 514 
miR135b and let7a (Applied Biosystems; Id 4427975) using qRT-PCR with taqman™ probes. Data is 515 
normalised to let7a and shown as fold change compared to vehicle treated mice. Sections were also 516 
taken for the analysis of TIMP-1 by qPCR and normalised to 18s as the internal housekeeper. Mouse 517 
TIMP-1 Primers: Forward: 5’-CAGTAAGGCCTGTAGCTGTGC-3’ and 5’-CTCGTTGATTTCGGGGAAC-3’. 518 
Statistical analysis 519 
Statistical analysis was performed between groups with a Student’s T test or Analysis of Variance 520 
(ANOVA) with P values <0.05 considered statistically significant * indicates significance in graphs. 521 
 522 
  523 
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Figure legends 524 
Figure 1 Dose response relationship of IL-13 and collagen induction. (A) Dermal fibroblasts were 525 
incubated with increasing doses of IL-13 in vitro and collagen1A1 was measured by qRT-PCR. Data 526 
shown is the fold change normalised to 18S housekeeping mRNA data is mean and standard 527 
deviation n=4. (B) Representative semi-quantitative RT-PCR of TGF-β1 after stimulation of cells 528 
with IL-13 for 24 hours PCR cycling was performed for 25 cycles and amplicons were 529 
electrophoresed on a 2% agarose gel with ethidium bromide incorporated within and imaged 530 
under UV light. 18S was used as an internal control NT: No template control, A untreated, B: IL-13 531 
(100 ng/ml) 24 hours treatment. (C) Fibroblast conditioned medium was analysed by ELISA for 532 
TSP-1 after removal of FCS and stimulation with IL-13 (100 ng/ml). TGF-β1 stimulation served as a 533 
positive control, data are the mean and SD from 4 independent experiments. (D) Fibroblast 534 
conditioned media was measured for TGF-β1 after stimulation with IL-13 (E) Dermal fibroblasts 535 
were treated with the TGF-βR blocker SB431542 or untreated and then stimulated with IL-13 (100 536 
ng/ml) and after 24 hours collagen1A1 mRNA was quantified by qRT-PCR and normalised to 18S. 537 
Data is the mean and SD n=4.  538 
Figure 2 IL-13 mediates collagen production via STAT6 signalling. (A) Dermal fibroblasts were 539 
transfected with smartpool siRNA against STAT6 or none targeting siRNA at equal concentrations 540 
after 24 hours medium was replaced with serum free medium containing IL-13 (100 ng/ml) after a 541 
further 24 hours in culture qRT-PCR was performed for collagen1A1. (B) Dermal fibroblasts were 542 
incubated with IL-13 (100 ng/ml), the STAT6 inhibitor (40 nM) and IL-13 or AS1517499 alone after 543 
24 hours qRT-PCR was performed for collagen1A1. Data is the mean and SD and is normalised to 544 
18S and untreated was set to 1 n=5. (C) Significant reduction in STAT6 after transfection with 545 
specific STAT6 siRNA. Data is fold change compared to scrambled none specific siRNA after 546 
transfection using DharmaFECT1 transfection. Data are the mean and SD n= 4 significant 547 
difference Students t test. (D). Representative western blot of STAT6 after scrambled control 548 
siRNA transfection or specific STAT6 siRNA after transfection using DharmaFECT1 n=4.  549 
Figure 3 miR-135b targets STAT6 to reduce collagen induction. (A) Dermal fibroblasts were 550 
transfected with miR135b mimics or concentration matched control miR (C. elegans) for 24 hours 551 
after which time the medium was replenished and contained 100 ng/ml recombinant IL-13 for a 552 
further 24 hours after which time the cells were harvested and qPCR was performed for 553 
collagen1A1 and normalised to 18s. Data is the mean and SD n=5 five different donors. (B) 75 nM 554 
of 135b mimic (low dose) or 150 nM (high dose) was transfected into dermal fibroblasts and after 555 
24 hours post transfection miR135b was quantitated by qRT-PCR, data is the mean and standard 556 
deviation. (C). 75nM of 135b mimic was transfected into dermal fibroblast and after 24 hours post 557 
transfection STAT6 was quantified by qRT-PCR, data is normalised to 18S and compared to 558 
scrambled miR transfected n=5 from five different individual donors. (D) STAT3 levels were 559 
analysed by qPCR after transfection with miR135b mimic or control miR 24 hours post 560 
transfection. Data is the mean and SD. ns: no significant difference between groups. 561 
Figure 4 Elevated miR135b target STAT6 SSc fibroblasts. (A)  Dermal fibroblasts or SSc fibroblasts 562 
were isolated and cultured within the first three passages the cells were lysed and a western blot 563 
was performed for STAT6. Representative western blot from 2 individual donors. GAPDH was used 564 
as the loading control for equal loading B) Healthy and SSc fibroblasts the RNA was harvested and 565 
qRT-PCR was performed for the expression of miR-135b and normalised to the expression of let7a. 566 
Data is the mean and SD n=3. No significant difference. (C) Down regulation of miR-135b by TGF-567 
β1. Dermal fibroblasts were stimulated with TGF-β1 (10 ng/ml) and after 24 hours the RNA was 568 
harvested and qRT-PCR was performed for miR-135b and normalised to the expression of let7a. 569 
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Data is the mean and SD n= 8. Significantly different compared to control (Student’s t test). D). SSc 570 
dermal fibroblasts express IL-4Rα chain. Fibroblasts were isolated and cultured and then RNA 571 
harvested then qRT-PCR was performed for IL-4Rα and normalised to 18S. Data is the mean and 572 
SD n=3. ns: no-significant difference between groups. 573 
Figure 5 SSc sera has reduced miR-135b levels. (A) SSc and healthy control serum was measured 574 
for miR-135b and let7a by qRT-PCR. Data is the mean and SD of HC=12 and SSc =15 (P =0.006 575 
Student’s t-test). (B) CD14+ cells were isolated and levels of miR-135b and let7a were measured by 576 
qRT-PCR. Data is the mean an SD n= 7 (P=0.03 Student’s t-test). (C) Bleomycin treated fibrotic mice 577 
have diminished miR-135b levels. C56/B Mice were vehicle or bleomycin treated and after fibrosis 578 
established skin biopsies were taken and the levels of miR135b were measured by RT qPCR and 579 
the data was normalised to let7a. Data is the mean and SD of five animals per group n= 5 (P= 580 
0.0001 Student’s t test). (D) TIMP-1 levels were analysed by qPCR. Data is the mean and SD of five 581 
animals per group n=5 (P= 0.0001 Student’s t test).  582 
Figure 6 Methylation regulates miR135b. A). Healthy dermal fibroblasts were treated with vehicle 583 
control (DMSO) or 10 μM 5’Aza’c for 5 days in culture after which qPCR was performed for miR135 584 
and let7a data is normalised to let7a and compared to vehicle control data is the mean and SD of 5 585 
individual donors n=5 (B) MiR133a levels were measured by qPCR and normalised to let7a. Data is 586 
the mean and SD of five individual donors n=5 C). Healthy and SSc dermal fibroblasts express 587 
similar levels of the DNA modifying enzyme TET1. Representative western blot for TET1 from two 588 
individual donors with limited SSc. GAPDH is used as the loading control n= 4. (D). Healthy or SSc 589 
dermal fibroblasts were analysed by qPCR for the genes Ezh2 and ASH1 and data normalised to 590 
18s. The data is the mean and SD n= 4 ns: no significant difference between groups E). SSc 591 
fibroblasts express higher MeCP2 levels. Heathy or SSc dermal fibroblasts were analysed by qPCR 592 
for MeCP2 expression and the data normalised to 18S. The data is the mean and SD n=4 (P=<0.001 593 
Student’s t test). (F). Western blot of fibroblasts treated with increasing doses of TGF-β1 for 594 
MeCP2 levels. Β actin served as a loading control.  595 
Figure 7 Treatment with the global hypomethylating compound 5’Aza’c reduced collagen levels. 596 
A). Healthy dermal fibroblasts were treated with DMSO vehicle control or 5’Aza’c for four days 597 
after which qPCR was performed for collagen1A1 and 18S. Data is the mean and SD of five donors 598 
and was normalised to 18S n=5. B). SSc dermal fibroblasts were treated with DMSO vehicle control 599 
or 5’Aza’c for four days after which qPCR was performed for collagen and 18S. Data is the mean 600 
and SD normalised to 18S n=4 C). SSc dermal fibroblasts were treated with DMSO control or 601 
5’Aza’c for four days after which CTGF and 18S was measured by qPCR. Data is the mean and SD 602 
n=4 ns: no significant difference between groups (Student’s t test). 603 
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